UBS raised the firm’s price target on QuidelOrtho (QDEL) to $35 from $31 and keeps a Neutral rating on the shares. A strong 2025-2026 respiratory season is a positive for QuidelOrtho heading into Q4, though some of the benefit may already be reflected after a recent 13% share move, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks